Comparative Pharmacology
Head-to-head clinical analysis: THIOLA versus THIOLA EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOLA versus THIOLA EC.
THIOLA vs THIOLA EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiola (tiopronin) acts as a reducing agent, breaking disulfide bonds in cystine stones and decreasing cystine excretion by forming a soluble disulfide complex with cystine, thereby reducing urinary cystine concentration.
THIOLA EC (tiopronin) is a reducing agent that breaks disulfide bonds in cystine, forming a mixed disulfide of tiopronin-cysteine, which is more soluble than cystine, thereby reducing cystine stone formation in the urine.
300 mg orally three times daily (total daily dose 900 mg) 1 hour before meals and at bedtime.
Oral administration of 300 mg (1 capsule) three times daily, 1 hour before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal half-life: 6-12 hours in patients with normal renal function; may be prolonged in renal impairment (up to 30 hours in severe CKD)
Primarily renal: approximately 60-70% of an administered dose is excreted in urine as unchanged drug or as the disulfide dimer. Minor biliary/fecal excretion accounts for <10%.
Renal: 80% as unchanged drug; biliary/fecal: <5%
Category C
Category C
Cystine Depleting Agent
Cystine Depleting Agent